1. Inicio
  2. Publicaciones
  3. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Muñoz-Martínez S
  • Sapena V
  • Forner A
  • Bruix J
  • Sanduzzi-Zamparelli M
  • Ríos J
  • Bouattour M
  • El Kassas M
  • Leal CRG
  • Mocan T
  • Nault JC
  • Alves RCP
  • Reeves HL
  • da Fonseca L
  • García-Juárez I
  • Pinato DJ
  • Varela M
  • Alqahtani SA
  • Alvares-da-Silva MR
  • Bandi JC
  • Rimassa L
  • Lozano M
  • González Santiago JM
  • Tacke F
  • Sala M
  • Anders M
  • Lachenmayer A
  • Piñero F
  • França A
  • Guarino M
  • Elvevi A
  • Cabibbo G
  • Peck-Radosavljevic M
  • Rojas Á
  • Vergara M
  • Braconi C
  • Pascual S
  • Perelló C
  • Mello V
  • Acevedo J
  • Villani R
  • Hollande C
  • Vilgrain V
  • Tawheed A
  • Ferguson Theodoro C
  • Sparchez Z
  • Blaise L
  • Viera-Alves DE
  • Watson R
  • Carrilho FJ
  • Moctezuma-Velázquez C
  • D'Alessio A
  • Iavarone M
  • Reig M

Unidades

Abstract

Background & Aims Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. Conclusions This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.

© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.

Datos de la publicación

ISSN/ISSNe:
1478-3223, 1478-3231

LIVER INTERNATIONAL  WILEY-BLACKWELL PUBLISHING, INC

Tipo:
Article
Páginas:
1891-1901
PubMed:
35608939

Citas Recibidas en Web of Science: 12

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • COVID-19; hepatocellular carcinoma; liver cancer; mortality

Campos de Estudio

Compartir